Literature DB >> 23284016

Genomic medicine: new frontiers and new challenges.

Maria D Pasic1, Sara Samaan, George M Yousef.   

Abstract

BACKGROUND: The practice of personalized medicine has made large strides since the introduction of high-throughput technologies and the vast improvements in computational biotechnology. The personalized-medicine approach to cancer management holds promise for earlier disease detection, accurate prediction of prognosis, and better treatment options; however, the early experience with personalized medicine has revealed important concerns that need to be addressed before research findings can be translated to the bedside. CONTENT: We discuss several emerging "practical" or "focused" applications of personalized medicine. Molecular testing can have an important positive impact on health and disease management in a number of ways, and the list of specific applications is evolving. This list includes improvements in risk assessment, disease prevention, identification of new disease-related mutations, accurate disease classification based on molecular signatures, selection of patients for enrollment in clinical trials, and development of new targeted therapies, especially for metastatic tumors that are refractory to treatment. Several challenges remain to be addressed before genomics information can be applied successfully in the routine clinical management of cancers. Further improvements and investigations are needed in data interpretation, extraction of actionable items, cost-effectiveness, how to account for patient heterogeneity and ethnic variation, and how to handle the risk of "incidental findings" in genetic testing.
SUMMARY: It is now clear that personalized medicine will not immediately provide a permanent solution for patient management and that further refinement in the applications of personalized medicine will be needed to address and focus on specific issues.
© 2012 American Association for Clinical Chemistry

Entities:  

Mesh:

Year:  2013        PMID: 23284016     DOI: 10.1373/clinchem.2012.184622

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  27 in total

1.  Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.

Authors:  Nicole M White-Al Habeeb; Ashley Di Meo; Andreas Scorilas; Fabio Rotondo; Olena Masui; Annetta Seivwright; Manal Gabril; Andrew H A Girgis; Michael A Jewett; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2015-06-03       Impact factor: 5.150

2.  S100A11 is a potential prognostic marker for clear cell renal cell carcinoma.

Authors:  Manal Gabril; Hala Girgis; Andreas Scorilas; Fabio Rotondo; Samantha Wala; Georg A Bjarnason; Qiang Ding; Andrew Evans; Eriny Tawedrous; Maria Pasic; Antonio Finelli; Sahar Al-Haddad; George M Yousef
Journal:  Clin Exp Metastasis       Date:  2016-01       Impact factor: 5.150

Review 3.  Urinary Biomarkers in Tumors: An Overview.

Authors:  Ilaria Cimmino; Sara Bravaccini; Claudio Cerchione
Journal:  Methods Mol Biol       Date:  2021

4.  All Along the Watchtower: a Case of Long QT Syndrome Misdiagnosis Secondary to Genetic Testing Misinterpretation.

Authors:  Benjamin M Helm; Mark D Ayers; Adam C Kean
Journal:  J Genet Couns       Date:  2018-08-16       Impact factor: 2.537

Review 5.  Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.

Authors:  Chenyu Mao; Yongfeng Ding; Nong Xu
Journal:  Mol Cell Biochem       Date:  2021-10-16       Impact factor: 3.396

6.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

7.  An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Authors:  Samantha Jane Wala; Jason Raj Karamchandani; Rola Saleeb; Andrew Evans; Qiang Ding; Rania Ibrahim; Michael Jewett; Maria Pasic; Antonio Finelli; Kenneth Pace; Evi Lianidou; George Makram Yousef
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

8.  Hodgkin disease therapy induced second malignancy susceptibility 6q21 functional variants in roma and hungarian population samples.

Authors:  Dalma Varszegi; Balazs Duga; Bela I Melegh; Katalin Sumegi; Peter Kisfali; Anita Maasz; Bela Melegh
Journal:  Pathol Oncol Res       Date:  2013-12-05       Impact factor: 3.201

Review 9.  An overview of recommendations and translational milestones for genomic tests in cancer.

Authors:  Christine Q Chang; Sharna R Tingle; Kelly K Filipski; Muin J Khoury; Tram Kim Lam; Sheri D Schully; John P A Ioannidis
Journal:  Genet Med       Date:  2014-10-23       Impact factor: 8.822

Review 10.  Urine as a Source of Liquid Biopsy for Cancer.

Authors:  Masanori Oshi; Vijayashree Murthy; Hideo Takahashi; Michelle Huyser; Maiko Okano; Yoshihisa Tokumaru; Omar M Rashid; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.